REGN Nov 2024 1050.000 call
| Previous close | 129.44 |
| Open | 129.44 |
| Bid | 113.90 |
| Ask | 120.90 |
| Strike | 1,050.00 |
| Expiry date | 2024-11-15 |
| Day's range | 129.44 - 129.44 |
| Contract range | N/A |
| Volume | |
| Open interest | 9 |
GlobeNewswireRegeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
At WCLC, five-year survival data to be presented on Libtayo (PD-1 inhibitor) first-line monotherapy in advanced non-small cell lung cancer At ESMO, longer-term results with investigational fianlimab (LAG-3 inhibitor) plus Libtayo from initial trial in advanced melanoma show high clinical activity, including deepening responses, per blinded independent central review Regeneron to host virtual investor event to discuss results alongside updates across its oncology portfolio on Monday, September 16
Insider MonkeyRegeneron Pharmaceuticals, Inc. (REGN): The Best Biotech Stock According to Hedge Funds?
We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other biotech stocks. As we have mentioned in our article, “10 Best Penny Stocks to Buy Under $1,” the […]
GuruFocus.comInsider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
On September 3, 2024, Arthur Ryan, Director at Regeneron Pharmaceuticals Inc (NASDAQ:REGN), executed a sale of 100 shares of the company at a price of $1178.69 per share. This transaction was reported in a recent SEC Filing. Following this sale, the insider now owns 17,682 shares of Regeneron Pharmaceuticals Inc.
